comprehensive -WSS

comprehensive

author：leisure time 2025-08-26 10:55:22 - browse：496

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Why H5N1 bird flu is keeping the CDC's top flu scientist awake

hotspot

WSS

Cigna, Humana reportedly in talks to merge

BIO selects John Crowley as new CEO

Diagnostic tests are hitting their mathematical limits

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

As biotech industry slumps, bioscience job market is upside down

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

entertainment

comprehensive

entertainment

In age of alternative facts, a scholarly course on calling out crap

Disappointing trial forces Pfizer to pivot on obesity medicine plans

DIEP, the 'gold standard' of breast reconstruction, is under threat

30 years of 'Listening to Prozac'

The high cost of giving birth even with insurance

CDC director unscathed in first congressional testimony

Medicare details structure of new drug price negotiation program

30 years of 'Listening to Prozac'

Cancer drug shortages should be causing more outrage

Organ aging and disease risk measured by new blood test

hotspot

Obesity drug from Roche shows promise in early study

Mayo Clinic plans $5B tech

U.K. Biobank has 500,000 peoples' genome sequences available

As H5N1 spreads in cows, experts warn against drinking raw milk

The EPA's new lead rule: How one expert crunched the numbers

Diagnostic tests are hitting their mathematical limits

hotspot

hotspot

entertainment

leisure time